TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M

Oncology Institute, Inc.

2026-Q1 EPS reported -$0.02 revenue$147,441,000

Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
Adjusted EBITDA loss $2.4M improved from $5.1M loss; EPS $(0.02) vs $(0.21).
Specialty Pharmacy revenue up 78% YoY; record Part D fills.
Medicare Advantage lives to reach 200,000 in Florida effective July 1, 2026.
CMS Enhancing Oncology Model saved ~$2M in period 3; full-year guidance reaffirmed.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001079973-26-000611
form_type: 8-K
ticker: TOI
cik: 0001799191
company_name: Oncology Institute, Inc.
filed_at: 2026-05-07T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.926291+00:00
generated_at: 2026-05-14T21:57:44.403901+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001079973-26-000611
json_url: https://secwatch.observer/filing/0001079973-26-000611.json
markdown_url: https://secwatch.observer/filing/0001079973-26-000611.md
text_url: https://secwatch.observer/filing/0001079973-26-000611.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/0001079973-26-000611-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/toi_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001079973-26-000611

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.